# Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Single and Multiple Doses of Linagliptin Tablets in Patients With Different Degrees of Renal Impairment in Comparison to Subjects With Normal Renal Function

> **NCT02191228** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 51 (actual)

## Conditions studied

- Renal Insufficiency

## Interventions

- **DRUG:** Linagliptin - single dose
- **DRUG:** Linagliptin - Multiple dose

## Key facts

- **NCT ID:** NCT02191228
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04
- **Primary completion:** 2010-02
- **Final completion:** —
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2014-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02191228

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02191228, "Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Single and Multiple Doses of Linagliptin Tablets in Patients With Different Degrees of Renal Impairment in Comparison to Subjects With Normal Renal Function". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02191228. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*